论文部分内容阅读
目的 观察足叶乙甙(VP16)联合环磷酰胺治疗雄激素抵抗性前列腺癌的疗效。 方法 9例经全雄激素阻断治疗失败,且排除Flutamide撤药综合征的雄激素抵抗性前列腺癌患者采用VP16加环磷酰胺联合化疗,VP16 50mg/d,环磷酰胺100mg/d,连续服用21d, 28d为1周期。直至病情进展或毒副反应患者无法耐受。 结果 9例平均随访7. 5个月,PSA有效4例,PSA治疗前(90. 5±43. 6)ng/ml,治疗后(24. 8±22. 2 )ng/ml,平均有效时间6. 8个月, 5例可测量软组织转移灶有效2例,CR1例,PR1例。毒副反应轻微。 结论 Vp16加环磷酰胺治疗雄激素抵抗性前列腺癌有一定疗效,毒副反应可以耐受。
Objective To observe the efficacy of etoposide (VP16) combined with cyclophosphamide in the treatment of androgen-resistant prostate cancer. Methods Nine male patients with androgen-refractory prostate cancer who had failed all-androgen blockade therapy and were excluded from Flutamide withdrawal syndrome were treated with VP16 plus cyclophosphamide combined with chemotherapy, VP16 50 mg / d and cyclophosphamide 100 mg / d 21d, 28d for a period. Until the progression of the disease or toxic patients can not tolerate. Results Nine patients were followed up for an average of 7.5 months. There were 4 patients with PSA effective before treatment (90.5 ± 43.6 ng / ml, 24.8 ± 22.2 ng / ml after treatment, mean effective time Six months, 5 cases were measurable soft tissue metastases in 2 cases, CR1 cases, PR1 cases. Toxicity minor. Conclusion Vp16 plus cyclophosphamide in the treatment of androgen-resistant prostate cancer has a certain effect, toxic side effects can be tolerated.